MGNX vs. EPZM, PBYI, RPTX, ICPT, PRTA, SAVA, ARQT, VRNA, ARCT, and BCYC
Should you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Epizyme (EPZM), Puma Biotechnology (PBYI), Repare Therapeutics (RPTX), Intercept Pharmaceuticals (ICPT), Prothena (PRTA), Cassava Sciences (SAVA), Arcutis Biotherapeutics (ARQT), Verona Pharma (VRNA), Arcturus Therapeutics (ARCT), and Bicycle Therapeutics (BCYC). These companies are all part of the "medical" sector.
MacroGenics (NASDAQ:MGNX) and Epizyme (NASDAQ:EPZM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
In the previous week, MacroGenics had 7 more articles in the media than Epizyme. MarketBeat recorded 7 mentions for MacroGenics and 0 mentions for Epizyme. Epizyme's average media sentiment score of 0.22 beat MacroGenics' score of 0.19 indicating that Epizyme is being referred to more favorably in the news media.
96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 76.5% of Epizyme shares are owned by institutional investors. 11.3% of MacroGenics shares are owned by insiders. Comparatively, 23.4% of Epizyme shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
MacroGenics has higher revenue and earnings than Epizyme. MacroGenics is trading at a lower price-to-earnings ratio than Epizyme, indicating that it is currently the more affordable of the two stocks.
MacroGenics has a net margin of -53.60% compared to Epizyme's net margin of -391.90%. MacroGenics' return on equity of -98.01% beat Epizyme's return on equity.
MacroGenics has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, Epizyme has a beta of -0.41, meaning that its stock price is 141% less volatile than the S&P 500.
MacroGenics presently has a consensus price target of $12.00, indicating a potential upside of 193.40%. Given MacroGenics' higher probable upside, equities analysts plainly believe MacroGenics is more favorable than Epizyme.
Epizyme received 56 more outperform votes than MacroGenics when rated by MarketBeat users. However, 63.12% of users gave MacroGenics an outperform vote while only 62.27% of users gave Epizyme an outperform vote.
Summary
MacroGenics beats Epizyme on 12 of the 17 factors compared between the two stocks.
Get MacroGenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MacroGenics Competitors List
Related Companies and Tools
